Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Benzinga (Wed, 15-Apr 4:51 AM ET)
Globe Newswire (Tue, 17-Mar 8:08 AM ET)
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Globe Newswire (Tue, 17-Feb 8:44 AM ET)
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Liminatus Pharma - Class A trades on the NASDAQ stock market under the symbol LIMN.
As of April 17, 2026, LIMN stock price declined to $0.22 with 3,371,736 million shares trading.
LIMN has a market cap of $8.62 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that LIMN belongs to (by Net Assets): VXF.
LIMN support price is $.21 and resistance is $.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LIMN shares will trade within this expected range on the day.
